Arechar Healthcare introduces the launch of T-Lamirenz and it contains 3 active ingredients: Tenofovir Disoproxil Fumarate, Lamivudine, and Efavirenz. This tablet is a combination of antiviral medicines used in the treatment of HIV (Human immunodeficiency virus) infection. This combination consists of 2 nucleoside reverse transcriptase inhibitors (ie, Lamivudine and Tenofovir) and 1 non-nucleoside reverse transcriptase inhibitor (Efavirenz). This medication helps keep HIV from reproducing and appears to slow down the destruction of the immune system. It may delay the development of problems that usually result from HIV infection. The manufacturing team of Arechar Healthcare signifies the key point of T-Lamirenz:-
-
T-Lamirenz (Tenofovir, Lamivudine, and Efavirenz) is a combination that contains 3 medications in one tablet. This medication is used to treat HIV (Human immunodeficiency virus) infection.
-
This medication helps in lowering your chance of getting an HIV infection and improves your quality of life.
-
This medication is a film-coated tablet that is available in the strength of Tenofovir 300mg + Lamivudine 300mg + Efavirenz 600mg.
-
Tenofovir Disoproxil Fumarate: NRT(nucleoside reverse transcriptase); following hydrolysis and phosphorylation, inhibits HIV-1 reverse transcriptase by competing with AMP as a substrate.
-
Lamivudine: NRT (nucleoside reverse transcriptase); following phosphorylation, inhibits HIV reverse transcriptase by viral DNA chain termination; cytosine analog.
-
Efavirenz: NNRT (non-nucleoside reverse transcriptase); activity against HIV-1 by binding to reverse transcriptase and consequently blocking the RNA-dependent and DNA-dependent DNA polymerase activities including HIV-1 replication; it does not require intracellular phosphorylation for antiviral activity.
“Arechar has always taken valuable steps ahead to serve the patients with the best and high-quality medicines at a very affordable range of prices, for serving humanity is the ultimate goal of our company,” said Mr. Harpreet Singh, Founder of Arechar Healthcare. “I feel happy to announce the launch of T-Lamirenz, which is one of the most efficient combinations of antiretrovirals to treat HIV.”
“By launching the best regimen for the treatment of HIV, we, at Arechar Healthcare, promise to work with the same dedication and commitment, because this world needs more solutions and treatment options to maintain good accessibility and affordability of pharmaceutical products,” said Mrs. Ruchika Rajbans Co-Founder of Arechar Healthcare
“I believe in achieving excellence through innovation” she added.